# BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

Study · id `cardio:ct-nct04666454` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04666454](<https://clinicaltrials.gov/study/NCT04666454>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04666454

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT04666454. Randomized; no masking; primary purpose treatment. Start 2020-12-14 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT04666454, source copy `cardio:ctgov-nct04666454-2024-12-02`, retrieved 2026-10-31)
- Started: 2020-12-14 (actual) (ClinicalTrials.gov record NCT04666454, source copy `cardio:ctgov-nct04666454-2024-12-02`, retrieved 2026-10-31)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT04666454, source copy `cardio:ctgov-nct04666454-2024-12-02`, retrieved 2026-10-31)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT04666454, source copy `cardio:ctgov-nct04666454-2024-12-02`, retrieved 2026-10-31)
- Countries: Denmark; Norway; Sweden (ClinicalTrials.gov record NCT04666454, source copy `cardio:ctgov-nct04666454-2024-12-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04666454-2024-12-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
- Condition: Takotsubo Syndrome
- Intervention (Drug): Adenosine
- Intervention (Drug): Dipyridamole 200 mg
- Intervention (Drug): Apixaban 5 mg Oral Tablet
- Intervention (Other): Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
- Lead sponsor: Vastra Gotaland Region
- Lead sponsor class: OTHER\_GOV
- Collaborator: Göteborg University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Vastra Gotaland Region (`cardio:org-vastra-gotaland-region`)
- Registry lists this organization as a collaborator: Göteborg University (`cardio:org-goteborg-university`)

## Provenance

Content hash: a08a0e39f0b4ae3ac1e04e34cd10c6088634beedb50cff9f72911c6ea4bbdb95
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
